FOLIRON” Folic Acid and Iron Capsules
Composition of FOLIRON:
Each hard gelatin capsule contains: Dried Ferrous Sulphate BP 150 mg
(As sustained-release pellets)
to Elemental Iron 47 mg
Folic acid BP 500 mcg
(As sustained-release pellets)
Excipients Q.S.
Approved colours are used in empty capsule shells and pellets.
Properties of FOLIRON:
FOLIRON is composed of two active ingredients that complement each other in preventing anaemia in pregnancy.
Ferrous sulphate is an iron salt that is essential for the formation of haemoglobin and for the oxidative processes of living tissues.
Folic acid is vitamin B9 of the vitamin B group. It is reduced in the body to tetrahydrofolate, which is a coenzyme for various metabolic processes, the most important of which are erythropoiesis and nucleoprotein synthesis. A deficiency of folic acid may lead to megaloblastic, macrocytic anaemia.
FOLIRON sustained release capsules are specially formulated to sustain the release of iron (over a period of several hours) to be in the small intestine (where absorption is greatest) rather than in the stomach where gastric irritation may be caused.
Indications of FOLIRON
FOLIRON is used for prophylaxis of iron and folic acid deficiency during pregnancy.
Dosage of FOLIRON
One FOLIRON capsule a day during pregnancy. Some pregnant patients may need a higher prophyactic dose of iron because of dietary or other factors.
If you miss a dose
- Take the missed dose as soon as possible.
- Do take the missed dose if it is almost time for your next scheduled dose. – Do not take two doses at the same time.
Contraindication of FOLIRON
This product should not be used for individuals having a hypersensitivity to any of its components.
Precautions of FOLIRON
Care should be taken in patients who may develop iron overloads, such as those with haemochromatosis, haemolytic anaemia, or red cell aplasia.
Failure to respond to treatment may indicate other causes of anaemia and should be further investigated.
Caution is recommended in patients with liver disease.
Pregnancy :
The use of any drug should be avoided in the first trimester of pregnancy unless considered essential.
Side Effects of FOLIRON
Dark stools are usual during iron therapy, and nausea and other symptoms of gastrointestinal irritation (such as anorexia, vomiting, abdominal discomfort, constipation, and diarrhoea) are sometimes encountered. However, FOLIRON capsules are designed to reduce the possibility of gastrointestinal irritation.
There have been rare reports of allergic reactions.
Overdosage
Treatment is necessary if more than 30mg of elemental iron per kilogram of body weight has been ingested. Symptoms may include abdominal pain, vomiting, diarrhoea, haematemesis, lethargy, coma, convulsions, and shock. Gastric lavage should be carried out in the early stages, or if this is not possible, vomiting should be induced. Give oral desferrioxamine (2g for a child or 5g for an adult) and demulcents.
If serum iron levels at 4 hours or more post-ingestion are over 5mg/L in a child or 8mg/L in an adult, or if the patient is in shock or coma, intramuscular or intravenous desferrioxamine should be used.
Symptomatic and supportive measures should be instituted as required. Drug Interactions
The presence of iron in the product may contribute to some drug interactinons when it is concurrently administered with some other agents.
Such potential interactions can be reduced by separating the administration of each product by several hours. These interactions include:
- Chelation of iron with tetracyclines, and thus the absorption of both agents is reduced.
- Absorption of iron may be reduced by trientine, magnesium trisilicate, and zinc (absorption of zinc may also be reduced).
- Iron may reduce the absorption of certain agents including some antibacterials (such as ciprofloxacin, levofloxacin, norfloxacin, and ofloxacine), bisphosphonates, some dopaminergics (such as entacapone and levodopa), and penicillamine.
- Iron may reduce the hypotensive effect of methyldopa.
Whereas, the presence of folic acid in the product may possibly result in a reduction of plasma concentrations of some antiepileptic agents such as phenobarbital, phenytoin, and primidone.
Presentation:
30 Capsules
Storage :
Store Below 30°C.
Protect from light and moisture.
Keep out of reach of children.
Marketed by:
PYXUS PHARMACEUTICALS PVT. LTD.
